Sanofi Genzyme Co-Pay Assistance Program

The Sanofi Genzyme Co-Pay Assistance Program helps individuals in the United States who are prescribed Cerezyme pay for their eligible out-of-pocket drug and infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including co-pays, co-insurance and deductibles, regardless of financial status*.

The program is open to individuals who:

  • Have commercial insurance
  • Have prescription drug coverage
  • Are prescribed treatment with Cerezyme 

To participate in this program you must complete an enrollment application. Once enrolled, Sanofi Genzyme will cover 100% of your eligible out-of-pocket Cerezyme drug costs up to the program maximum.

Who is eligible for the Co-Pay Assistance Program?

Regardless of financial status, the program is open to individuals who:

  • Have primary commercial insurance
  • Are prescribed treatment with Cerezyme

You are NOT eligible if you:

  • Have coverage or prescriptions paid for in part or full under any state or federally funded healthcare program including:
    • Medicare
    • Medicare Advantage Plans
      (Example: FreedomBlue offered through Blue Cross Blue Shield)
    • Medicare Part D
    • Medicaid
    • Medigap
    • Veterans Affairs, Department of Defense or TRICARE
    • In accordance with State law, the Program does not reimburse infusion-related charges for patients residing in Massachusetts, Michigan, Minnesota and Rhode Island.

Submit your application today or to learn more about the program call 1-800-745-4447, option 3.

*No claim for reimbursement of any out-of-pocket expense covered by the Co-Pay Program may be submitted to any third-party payer, where public or private. The Co-Pay Program is available only in the United States and cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-Pay Benefits are not transferable. This program assists patients with their out-of-pocket drug and infusion-related costs of their enzyme replacement therapy treatment only and does not cover or provide support for the cost of MD office visits/evaluations, nursing services/observation periods, blood work, x-rays or other testing, pre-medications/other medications, Epi pens, transportation or other related services. Sanofi Genzyme reserves the right to make eligibility decisions, set program maximums, and rescind, revoke, or amend this program without notice.

The Co-Pay Assistance Enrollment Process

STEP 1: Complete the program application here.

  •  Helpful information to have on hand when you apply:
    • Your treating Physician's contact information
    • Your health insurance card

STEP 2: Your eligibility is verified

  • Your application will be reviewed for eligibility. If you are eligible, you
    will be automatically enrolled in the program. Enrollment in the program
    is subject to confirmation of eligibility.

STEP 3: You're enrolled!

  • Once approved, you will receive a confirmation letter and an
    enrollment card within 7-10 days. Contact your Sanofi Genzyme Case
    Manager if you do not receive this confirmation. Your doctor or specialty
    pharmacy will also receive a phone call with instructions on how to
    submit claims for reimbursement through the program.
    Your enrollment in the program is effective from the date of approval
    through the end of the calendar year (calendar year is January 1 through
    December 31).


Current Enrollees

If you are currently enrolled in our Co-Pay Assistance Program you will
be automatically enrolled in the program for the next calendar year
(January 1 through December 31) unless you decide to opt out of the
program or your insurance coverage changes.


Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).

You may report side effects to the FDA at 1-800-FDA-1088.

Reference 1. Data on file. Genzyme Corporation; Cambridge, MA.